Endometrial safety of ultra-low-dose Vagifem 10 μg in postmenopausal women with vaginal atrophy

Climacteric

Volumn 13, Issue 3, 2010, Pages 228-237

  Ulrich, L S G ^a   Naessen, T ^b   Elia, D ^c   Goldstein, J A ^d   Eugster Hausmann, M ^e  

^a Rigshospitalet   (Denmark)

^b UPPSALA UNIVERSITY   (Sweden)

^c Gynecologue   (France)

^d NOVO NORDISK INC   (United States)

^e Novo Nordisk FemCare AG   (Switzerland)

Author keywords

Endometrial safety; Hormone replacement therapy; Hormone therapy; Ultra low dose estradiol; Vaginal atrophy; Vaginal therapy

Indexed keywords

ESTRADIOL; FOLLITROPIN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG USE; DRUG WITHDRAWAL; ENDOMETRIUM BIOPSY; ENDOMETRIUM POLYP; ESTRADIOL BLOOD LEVEL; FEMALE; FOLLITROPIN BLOOD LEVEL; HISTOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PATIENT COMPLIANCE; POSTMENOPAUSE; PRIORITY JOURNAL; TABLET FORMULATION; TRANSVAGINAL ECHOGRAPHY; VAGINA ATROPHY; VULVOVAGINAL DISCOMFORT;

ADMINISTRATION, INTRAVAGINAL; ATROPHY; BIOPSY; ENDOMETRIUM; ESTRADIOL; ESTROGENS; FEMALE; HUMANS; MIDDLE AGED; POSTMENOPAUSE; VAGINA;

EID: 77951858323     PISSN: 13697137     EISSN: 14730804     Source Type: Journal    
DOI: 10.3109/13697137.2010.481058     Document Type: Article

References (37)

1. Nelson HD. Menopause. Lancet 2008;371:760-770
2. Anderson GL, Judd HL, Kaunitz AM, et al. Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women's Health Initiative randomized trial. JAMA 2003;290:1739-1748
3. Beral V, Bull D, Reeves G. Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet 2005;365:1543-1551
4. The Writing Group for the PEPI Trial. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/ Progestin Interventions (PEPI) Trial. JAMA 1996;275: 370-375
5. The North American Menopause Society. The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women: 2007 position statement of The North American Menopause Society. Menopause 2007;14: 355-369
6. Cardozo L, Bachmann G, McClish D, Fonda D, Birgerson L. Meta-analysis of estrogen therapy in the management of urogenital atrophy in postmenopausal women: second report of the Hormones and Urogenital Therapy Committee. Obstet Gynecol 1998;92:722-727
7. Suckling J, Lethaby A, Kennedy R. Local oestrogen for vaginal atrophy in 22 postmenopausal women. Cochrane Database Syst Rev 2006;(4):CD001500
8. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance For Industry, Labeling Guidance for Noncontraceptive Estrogen Drug Products for the Treatment of Vasomotor Symptoms and Vulvar and Vaginal Atrophy Symptoms - Prescribing Information for Health Care Providers and Patient Labeling. November 2005, Revision 4
9. Pines A, Sturdee DW, Birkhaüser MH, Schneider HP, Gambacciani M, Panay N. IMS updated recommendations on postmenopausal hormone therapy. Climacteric 2007; 10:181-194 (Pubitemid 46752441)
10. Utian WH, Archer DF, Bachmann GA, et al. Estrogen and progestogen use in postmenopausal women: July 2008 position statement of The North American Menopause Society. Menopause 2008;15:584-602
11. Skouby SO, Al-Azzawi F, Barlow D, et al. Climacteric medicine: European Menopause and Andropause Society (EMAS) 2004/2005 position statements on peri- and postmenopausal hormone replacement therapy. Maturitas 2005;51:8-14
12. Simon J, Nachtigall L, Gut R, Lang E, Archer DF, Utian W. Effective treatment of vaginal atrophy with an ultralow- dose estradiol vaginal tablet. Obstet Gynecol 2008;112:1053-1060
13. Elsandabesee D, Greenwood P. The performance of Pipelle endometrial sampling in a dedicated postmenopausal bleeding clinic. J Obstet Gynaecol 2005;25:32-34
14. Youssif SN, McMillan DL. Outpatient endometrial biopsy: the pipelle. Br J Hosp Med 1995;54:198-201
15. Hanley JA, Lippman-Hand A. If nothing goes wrong, is everything all right? Interpreting zero numerators. JAMA 1983;249:1743-1745
16. Weiderpass E, Baron JA, Adami HO, et al. Low-potency oestrogen and risk of endometrial cancer: a case-control study. Lancet 1999;353:1824-1828
17. Bachmann G, Bouchard C, Hoppe D, et al. Efficacy and safety of low-dose regimens of conjugated estrogens cream administered vaginally. Menopause 2009;16:719-727
18. Mettler L, Olsen PG. Long-term treatment of atrophic vaginitis with low-dose oestradiol vaginal tablets. Maturitas 1991;14:23-31
19. Viola AS, Gouveia D, Andrade L, Aldrighi JM, Viola CF, Bahamondes L. Prevalence of endometrial cancer and hyperplasia in non-symptomatic overweight and obese women. Aust N Z J Obstet Gynaecol 2008;48:207-213
20. Smith-Bindman R, Weiss E, Feldstein V. How thick is too thick? When endometrial thickness should prompt biopsy in postmenopausal women without vaginal bleeding. Ultrasound Obstet Gynecol 2004;24:558-565
21. Mainini G, Scaffa C, Rotondi M, Messalli EM, Quirino L, Ragucci A. Local estrogen replacement therapy in postmenopausal atrophic vaginitis: efficacy and safety of low dose 17beta-estradiol vaginal tablets. Clin Exp Obstet Gynecol 2005;32:111-113
22. Salminen HS, Saaf ME, Johansson SE, Ringertz H, Strender LE. The effect of transvaginal estradiol on bone in aged women: a randomised controlled trial. Maturitas 2007;57:370-381
23. Trevoux R, De BJ, Castanier M, Nahoul K, Soule JP, Scholler R. Endometrium and plasma hormone profile in the peri-menopause and post-menopause. Maturitas 1986;8:309-326
24. Kurman RJ, Kaminski PF, Norris HJ. The behavior of endometrial hyperplasia. A long-term study of "untreated" hyperplasia in 170 patients. Cancer 1985;56:403-412
25. Pickar JH, Yeh IT, Wheeler JE, Cunnane MF, Speroff L. Endometrial effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate: two-year substudy results. Fertil Steril 2003;80:1234-1240
26. Rioux JE, Devlin C, Gelfand MM, Steinberg WM, Hepburn DS. 17beta-estradiol vaginal tablet versus conjugated equine estrogen vaginal cream to relieve menopausal atrophic vaginitis. Menopause 2000;7:156-161
27. Weisberg E, Ayton R, Darling G, et al. Endometrial and vaginal effects of low-dose estradiol delivered by vaginal ring or vaginal tablet. Climacteric 2005;8:83-92
28. Bachmann G, Bouchard C, Hoppe D, et al. Efficacy and safety of low-dose regimens of conjugated estrogens cream administered vaginally. Menopause 2009;16:719-727
29. Dreisler E, Stampe SS, Ibsen PH, Lose G. Prevalence of endometrial polyps and abnormal uterine bleeding in a Danish population aged 20-74 years. Ultrasound Obstet Gynecol 2009;33:102-108
30. Tourgeman DE, Slater CC, Stanczyk FZ, Paulson RJ. Endocrine and clinical effects of micronized estradiol administered vaginally or orally. Fertil Steril 2001;75: 200-202
31. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for Industry, Estrogen and Estrogen/Progestin Drug Products to Treat Vasomotor Symptoms and Vulvar and Vaginal Atrophy Symptoms - Recommendation for Clinical Evaluation. January 2003
32. Haspels AA, Luisi M, Kicovic PM. Endocrinological and clinical investigations in post-menopausal women following administration of vaginal cream containing oestriol. Maturitas 1981;3:321-327
33. Kvorning I, Daugbjerg NU, Jensen HK, Saurbrey N, Fink B. Pharmaceutical development of low-dose estradiol vagitories in The Urogenital Oestrogen Deficiency Syndrome. Proceedings of International Workshop, Copenhagen, November 7th 1986 (editors Goran Samsioe and Peter Bonne Eriksen). ISBN 87-87161-03-6. Copyright NOVO Industry A/S 1987. The workshop was organized by NOVO Industry
34. Nilsson K, Heimer G. Low-dose oestradiol in the treatment of urogenital oestrogen deficiency - a pharmacokinetic and pharmacodynamic study. Maturitas 1992;15:121-127
35. Burger H. The menopausal transition - endocrinology. J Sex Med 2008;5:2266-2273
36. Foidart JM, Vervliet J, Buytaert P. Efficacy of sustainedrelease vaginal oestriol in alleviating urogenital and systemic climacteric complaints. Maturitas 1991;13:99-107
37. Nachtigall LE. Clinical trial of the estradiol vaginal ring in the US. Maturitas 1995;22(Suppl):S43-7